Company / Interest Expense
TEVA PHARMACEUTICAL INDUSTRIES LTD Interest Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$916.0M
FY2025
5-year range
$891.0M / $1.0B
FY2021-FY2025
Trend
-8.6%
vs FY2024
Sector context
#5 of 44
Health Care
What the data says
TEVA PHARMACEUTICAL INDUSTRIES LTD's interest expense of $916M is higher than 89% of companies in the Health Care sector (FY2025). Interest Expense has fluctuated over the past 10 years, ranging from $546M in FY2016 to $1.0B in FY2023.
Based on SEC 10-K filings.
$916M in FY2025 with a 5-year CAGR of +0.3%. Top quartile in the Health Care sector.
Improved from $1.0B to $916M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- +0.3%
- 10-Year CAGR
- -
Sector benchmark
+214.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +0.3%, indicating consistent growth.
- In FY2025, interest expense decreased 8.6% year-over-year.
- Ranks #5 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $916.0M | -8.6% |
| FY2024 | $1.0B | -2.6% |
| FY2023 | $1.0B | +10.6% |
| FY2022 | $930.0M | +4.4% |
| FY2021 | $891.0M | -1.1% |
| FY2020 | $901.0M | +9.6% |
| FY2019 | $822.0M | -10.7% |
| FY2018 | $920.0M | +5.1% |
| FY2017 | $875.0M | +60.3% |
| FY2016 | $546.0M | +102.2% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026